AFIRMELLE Drug Patent Profile
✉ Email this page to a colleague
When do Afirmelle patents expire, and when can generic versions of Afirmelle launch?
Afirmelle is a drug marketed by Aurobindo Pharma and is included in one NDA.
The generic ingredient in AFIRMELLE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AFIRMELLE?
- What are the global sales for AFIRMELLE?
- What is Average Wholesale Price for AFIRMELLE?
Summary for AFIRMELLE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| DailyMed Link: | AFIRMELLE at DailyMed |
US Patents and Regulatory Information for AFIRMELLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | AFIRMELLE | ethinyl estradiol; levonorgestrel | TABLET;ORAL-28 | 206886-001 | Nov 14, 2016 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
